MedTrace Logo

A Study of IMR-687 in Healthy Adult Volunteers

NCT02998450 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-05-15

No results posted yet for this study

Summary

The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.

Conditions

Interventions

DRUG

IMR-687

1 of 6 possible single doses administered orally following overnight fast

DRUG

Placebo Oral Capsule

Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Imara, Inc.

    collaborator INDUSTRY

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Regulatory Operations · Cardurion Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-18
Primary Completion
2017-07-08
Completion
2017-07-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998450 on ClinicalTrials.gov